Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:DAWNNASDAQ:MRUSNASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$23.37+2.7%$22.99$14.75▼$26.16$2.85B0.71.11 million shs1.55 million shsDAWNDay One Biopharmaceuticals$6.45-4.6%$7.70$6.26▼$17.14$653.79M-1.241.08 million shs1.34 million shsMRUSMerus$41.32-3.4%$43.51$33.19▼$61.61$2.86B0.94719,048 shs556,197 shsXENEXenon Pharmaceuticals$35.13-1.2%$34.59$26.74▼$46.00$2.69B1.21472,352 shs1.06 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+2.64%-5.92%+2.77%+2.05%+58.76%DAWNDay One Biopharmaceuticals-4.66%-18.66%-11.28%-46.47%-60.69%MRUSMerus-3.39%-6.49%+4.45%+0.17%-12.25%XENEXenon Pharmaceuticals-1.15%-8.23%+11.21%-10.41%-18.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.7001 of 5 stars3.62.00.03.92.93.32.5DAWNDay One Biopharmaceuticals2.4402 of 5 stars4.60.00.00.02.62.50.0MRUSMerus3.2068 of 5 stars4.63.00.00.03.21.70.0XENEXenon Pharmaceuticals2.6624 of 5 stars4.51.00.00.03.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2938.15% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$30.57373.98% UpsideMRUSMerus 3.13Buy$85.15106.08% UpsideXENEXenon Pharmaceuticals 3.00Buy$56.2260.04% UpsideCurrent Analyst Ratings BreakdownLatest DAWN, MRUS, CPRX, and XENE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/7/2025DAWNDay One BiopharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$25.005/7/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $27.005/7/2025XENEXenon PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/5/2025XENEXenon PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/17/2025XENEXenon PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $52.004/9/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$83.00 ➝ $83.004/3/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.003/28/2025MRUSMerusGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$109.00 ➝ $109.003/25/2025DAWNDay One BiopharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$39.00 ➝ $27.00(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$491.73M5.80$2.18 per share10.72$3.30 per share7.08DAWNDay One Biopharmaceuticals$161.92M4.04N/AN/A$3.98 per share1.62MRUSMerus$36.13M79.11N/AN/A$6.17 per share6.70XENEXenon Pharmaceuticals$9.43M285.34N/AN/A$14.18 per share2.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.3119.8110.973.3131.01%40.79%34.87%N/ADAWNDay One Biopharmaceuticals-$188.92M-$0.71N/AN/AN/AN/A-22.40%-19.79%7/8/2025 (Estimated)MRUSMerus-$154.94M-$3.27N/AN/AN/A-680.61%-38.89%-31.16%5/14/2025 (Estimated)XENEXenon Pharmaceuticals-$182.39M-$3.02N/AN/AN/AN/A-24.69%-23.68%5/12/2025 (Estimated)Latest DAWN, MRUS, CPRX, and XENE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025XENEXenon Pharmaceuticals-$0.94N/AN/AN/A$1.64 millionN/A5/6/2025Q1 2025DAWNDay One Biopharmaceuticals-$0.46-$0.35+$0.11-$0.35$30.28 million$30.76 million2/27/2025Q4 2024MRUSMerus-$0.89-$0.41+$0.48-$0.41$10.57 million$9.14 million2/27/2025Q4 2024XENEXenon Pharmaceuticals-$0.89-$0.84+$0.05-$0.84$0.31 millionN/A2/25/2025Q4 2024DAWNDay One Biopharmaceuticals-$0.35-$0.69-$0.34-$0.69$27.11 million$29.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92DAWNDay One BiopharmaceuticalsN/A14.6214.55MRUSMerusN/A8.328.32XENEXenon PharmaceuticalsN/A22.2122.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%DAWNDay One Biopharmaceuticals87.95%MRUSMerus96.14%XENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%DAWNDay One Biopharmaceuticals6.20%MRUSMerus4.57%XENEXenon Pharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.96 million106.15 millionOptionableDAWNDay One Biopharmaceuticals60101.36 million92.38 millionOptionableMRUSMerus3769.18 million65.34 millionOptionableXENEXenon Pharmaceuticals21076.59 million72.03 millionOptionableDAWN, MRUS, CPRX, and XENE HeadlinesRecent News About These CompaniesDriehaus Capital Management LLC Has $177.21 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 10 at 6:59 AM | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Research Coverage Started at Chardan CapitalMay 10 at 1:47 AM | americanbankingnews.comWhat to Expect from Xenon Pharmaceuticals's EarningsMay 9 at 12:38 PM | benzinga.comChardan Capital Initiates Coverage on Xenon Pharmaceuticals (NASDAQ:XENE)May 9 at 8:10 AM | marketbeat.com169,132 Shares in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Acquired by Deep Track Capital LPMay 9 at 7:51 AM | marketbeat.comRaymond James Financial Inc. Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 9 at 3:27 AM | marketbeat.comBraidwell LP Boosts Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 8 at 6:29 AM | marketbeat.comChardan Capital Initiates Coverage of Xenon Pharmaceuticals (XENE) with Buy RecommendationMay 7 at 8:41 PM | msn.comXenon Pharmaceuticals' (XENE) Outperform Rating Reiterated at William BlairMay 7 at 12:12 PM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Algert Global LLCMay 7 at 5:23 AM | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Avidity Partners Management LPMay 6, 2025 | marketbeat.comAquatic Capital Management LLC Takes Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 6, 2025 | marketbeat.comVoya Investment Management LLC Grows Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 6, 2025 | marketbeat.comRenaissance Technologies LLC Decreases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 6, 2025 | marketbeat.comXenon to Report Q1 2025 Financial Results on May 12, 2025May 5, 2025 | financialpost.comXenon to Report Q1 2025 Financial Results on May 12, 2025May 5, 2025 | globenewswire.comWall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?May 5, 2025 | zacks.comAllostery Investments LP Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 4, 2025 | marketbeat.comAlly Bridge Group NY LLC Cuts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Invests $23.52 Million in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)May 4, 2025 | marketbeat.comXenon Pharmaceuticals (XENE) Projected to Post Earnings on ThursdayMay 3, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDAWN, MRUS, CPRX, and XENE Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$23.37 +0.61 (+2.68%) As of 05/9/2025 04:00 PM EasternCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Day One Biopharmaceuticals NASDAQ:DAWN$6.45 -0.31 (-4.59%) As of 05/9/2025 04:00 PM EasternDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Merus NASDAQ:MRUS$41.32 -1.45 (-3.39%) As of 05/9/2025 03:51 PM EasternMerus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Xenon Pharmaceuticals NASDAQ:XENE$35.13 -0.41 (-1.15%) As of 05/9/2025 03:52 PM EasternXenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings Strategists Say Hold: Stocks May Beat the 'Sell in May' Trend Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock GlobalFoundries Stock Hits Bottom: Is a Rebound Coming? What the ExtraHop Deal Means for CrowdStrike DoorDash’s Uptrend Is Gaining Momentum in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
